Scholarly article on topic 'New Simple Spectrophotometric Method for the Simultaneous Estimation of Paracetamol and Flupirtine Maleate in Pure and Pharmaceutical Dosage Form'

New Simple Spectrophotometric Method for the Simultaneous Estimation of Paracetamol and Flupirtine Maleate in Pure and Pharmaceutical Dosage Form Academic research paper on "Chemical sciences"

CC BY
0
0
Share paper
OECD Field of science
Keywords
{""}

Academic research paper on topic "New Simple Spectrophotometric Method for the Simultaneous Estimation of Paracetamol and Flupirtine Maleate in Pure and Pharmaceutical Dosage Form"

Hindawi Publishing Corporation International Journal of Spectroscopy Volume 2014, Article ID 968420, 6 pages http://dx.doi.org/10.1155/2014/968420

Research Article

New Simple Spectrophotometric Method for

the Simultaneous Estimation of Paracetamol and Flupirtine

Maleate in Pure and Pharmaceutical Dosage Form

P. Giriraj and T. Sivakkumar

Department of Pharmacy, Faculty of Engineering and Technology, Annamalai University, Tamil Nadu 608002, India

Correspondence should be addressed to T. Sivakkumar; sivat27@rediffmail.com

Received 5 February 2014; Revised 24 March 2014; Accepted 19 April 2014; Published 12 May 2014

Academic Editor: Craig J. Eckhardt

Copyright © 2014 P. Giriraj and T. Sivakkumar. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

A new, simple, precise, accurate, reproducible, and efficient Vierordt's method or simultaneous equation method was developed and validated for simultaneous estimation of paracetamol and flupirtine maleate in pure and pharmaceutical dosage form. The method was based on the measurement of absorbance at two wavelengths 245 nm and 344.5 nm, Amax of paracetamol and flupiritine maleate in 0.1 N HCl correspondingly. Calibration curves of paracetamol and flupiritine maleate were found to be linear in the concentration ranges of 5-15 ^g/mL and 1.53-4.61 ^g/mL, respectively, with their correlation coefficient values (R2) 0.999. LOD and LOQ were 185.90 ng/mL and 563.38 ng/mL for paracetamol and 78.89 ng/mL and 239.06 ng/mL for flupiritine maleate. In the precision study, the % RSD value was found within limits (RSD < 2%). The percentage recovery at various concentration levels varied from 99.18 to 100.02% for paracetamol and 98.47 to 100.09% for flupiritine maleate confirming that the projected method is accurate. It could be concluded from the results obtained in the present investigation that this method for simultaneous estimation of paracetamol and flupirtine maleate in pure and tablet dosage form is simple, accurate, precise, and economical. The proposed method can be applied successfully for the simultaneous estimation of paracetamol and flupiritine maleate in pure and pharmaceutical dosage form.

1. Introduction

Paracetamol (PAR) is chemically N-(4-hydroxyphenyl)acet-amide (Figure 1). It is centrally and peripherally acting non-opioid analgesic and antipyretic [1]. Flupirtine maleate (FLU)ischemicallyethyl2-amino-6-[(4-fluorobenzyl) amino] pyridin-3-yl carbamate maleate (Figure 2). FLU is a unique centrally acting nonopioid analgesic with muscle relaxants and neuroprotective properties. It is an aminopyridine

derivative [2].

Literature survey publicized that certain UV [2-9], HPLC [1, 10-16], HPTLC [17], and LC-MS [18] methods were reported for the estimation of these drugs either individually or combined with other drugs. On the other hand simultaneous equation (SE) or Vierordt's method was not reported for this new combination. Simultaneous equation (SE) or Vierordt's method is typically applied to estimate drug combinations that contain two drugs or more than two drugs in combined dosage form. Technical hitches involved in this method is

very less when compared to other UV methods. Hence an attempt has been made to develop a simple and a reproducible SE method to ensure the safety and efficacy of this selected combination. This developed method was fully validated and applied successfully for the simultaneous estimation of PAR and FLU in pure and pharmaceutical dosage form.

2. Materials and Methods

2.1. Apparatus. Shimadzu 1650 UV-VIS double beam spectrophotometer with UV probe software was used. Absorb-ance measurements were recorded with a pair of 1 cm matched quartz cells.

2.2. Chemicals and Reagents. Paracetamol and flupirtine maleate were kindly supplied by Safetab pharma (Pondicher-ry, India) and analytical grade Hydrochloric acid (S.D fine chemical Ltd., Mumbai, India) was used. The marketed tablet

Figure 1: Structure of PAR.

-nh2 T

Figure 2: Structure of FLU.

(LUPIRTINE) used contains 325 mg paracetamol and 100 mg flupiritine maleate and was manufactured by Lupin Pvt Ltd. (Mumbai, India).

2.3. Preparations of Standard Stock Solutions. Standard stock solution of paracetamol (125 ^g/mL) was prepared by dissolving 12.50 mg of paracetamol in 60 mL of 0.1 N HCL. Resulting solution was sonicated for 10 minutes and the final volume was adjusted to 100 mL with 0.1 N HCL. From this standard stock solution, 2 mL was withdrawn and diluted to 25 mL using same solvent to get working standard solution of 10 ^g/mL. Similarly standard stock solution of flupirtine maleate (38.46 ^g/mL) was prepared by dissolving 3.846 mg of flupirtine maleate in 60 mL of 0.1 N HCL. Resulting solution was sonicated for 10 minutes and the final volume was adjusted to 100 mL with 0.1 N HCL. This solution was further diluted to get working standard solution of 3.07 ^g/mL.

2.4. Simultaneous Equation Method Development. Working solutions of both drugs were scanned in the UV range 200400 nm. The overlay spectra of both drugs were recorded (Figure 3). From overlain spectra, wavelengths 245 nm (Amax of PAR) and 344.5 nm (Amax of FLU) were selected for analysis of both drugs using simultaneous equation method (Ar 245 nm for PAR and A2-344.5 nm for FLU). Consequently, it may be possible to determine both drugs by the technique of from method or simultaneous equation method[19-22].

Five standard solutions having concentrations of 5, 7.5, 10, 12.5, and 15 ^g/mL for PAR and 1.53, 2.30, 3.07, 3.84, and 4.61 ^g/mL for FLU were prepared in 0.1 N HCL and their corresponding absorbance was measured at 245 nm and 344.5 nm. The concentration of drugs x (PAR) and y (FLU) in sample solutions were determined by the SE method using the following formula:

A2ay! - Aiay2

Cx =--axxay 2,

ax2ay1 2

7 ax2ay1

where Cx and Cy are the concentration of PAR and FLU, A1 and A 2 are the absorbance of sample solution at 245 nm and 344.5 nm, respectively, ax1 and ax2 are absorptivity of PAR at 245 nm and 344.5 nm, and ay 1 and ay2 are absorptivity of FLU at 245 nm and 344.5 nm, respectively.

2.5. Determination of Absorptivity Value. The absorptivity value of PAR and FLU from each solution was calculated using following formula [23] and the results were presented in Tables 1 and 2:

,, Absorbance , .

Absorptivity =- (gm/100mL).

<1ay 2,

Developed method was validated as per ICH [24] guidelines.

3. Results and Discussion

3.1. Specificity. Specificity of the method was dogged by measuring the absorbance of PAR and FLU individually at 245 nm and 344.5 nm against the blank and synthetic excipients and their absorbance was compared with the blank and synthetic excipients. No interference was observed at 245 nm and 344.5 nm indicating that the method is specific.

3.2. Linearity. The calibration curves (Figures 4 and 5) were constructed by plotting the absorbance versus the concentration ranges from 5, 7.5, 10, 12.5, to 15 ^g/mL and 1.53, 2.30, 3.07, 3.84, to 4.61 ^g/mL for PAR and FLU. It was found that, the calibration curves were linear in these concentration ranges with their correlation coefficient values (R2) 0.999 for PAR and FLU. Results revealed that good correlation exists between the concentration of the sample and their absorbance.

3.3. Accuracy. Accuracy of the method was determined by applying this described method to synthetic excipients containing known amount of each drug corresponding to 50%, 75%, 100%, 125%, and 150% of the label claim of PAR and FLU. The amount of PAR and FLU recovered in each level was calculated and results were presented in Table 3.

Table 1: Absorptivity value for PAR.

Concentration (^g/mL) Absorbance Aj - 245 nm Absorptivity Aj - 245 nm Absorbance A2 - 344.5 nm Absorptivity A2 - 344.5

5 0.336 672.00 0.000 0.00

7.5 0.503 670.66 0.001 1.33

10 0.674 674.00 0.000 0.00

12.5 0.835 668.00 0.001 0.80

15 1.011 674.00 0.000 0.00

Absorptivity for Aj 671.73 Absorptivity for A2 0.42

Table 2: Absorptivity value for FLU.

Concentration (^g/mL) Absorbance Aj - 245 nm Absorptivity Aj - 245 nm Absorbance A2 - 344.5 nm Absorptivity A2 - 344.5 nm

1.53 0.054 351.01 0.075 487.51

2.30 0.081 351.01 0.115 498.35

3.07 0.108 351.01 0.152 494.01

3.84 0.134 348.41 0.187 486.21

4.61 0.163 353.18 0.225 487.51

Absorptivity for Aj 350.92 Absorptivity for A2 490.72

Developed method was validated as per ICH [24] guidelines.

Table 3: Recovery results for PAR and FLU.

Concentration (%) PAR FLU

PAR/FLU (« = 3) Added amount (mg) Amount recovered (mg) Amount recovered (%) RSD (%) Added amount (mg) Amount recovered (mg) Amount recovered (%) RSD (%)

50 6.25 6.27 100.42 ± 0.32 0.32 1.92 1.91 99.50 ± 0.76 0.76

75 9.37 9.39 110.16 ±0.17 0.17 2.88 2.61 100.09 ±0.51 0.50

100 12.50 12.54 100.34 ± 15 0.15 3.84 3.82 99.50 ± 0.38 0.38

125 15.62 15.49 99.18 ±0.18 0.19 4.80 4.76 99.15 ±0.61 0.61

150 18.75 18.81 100.35 ±0.07 0.07 5.76 5.68 98.47 ± 0.50 0.51

The percentage recovery varied from 99.18 to 100.02 for PAR and 98.47 to 100.09 for FLU, indicating good accuracy of the method.

Figure 3: Overlain spectra of PAR (a) and FLU (b).

1.2 -, 1 -

„ 0.8-

•fi 0.6 4

Paracetamol

y = 0.0672x - 0.001 R2 = 0.999

5 10 15

Concentration (^g/mL)

+ Series 1 - Linear (series 1)

Figure 4: Calibration graph for PAR.

cna 0.15 ba

sb 0.1

Flupirtine

y = 0.0483x + 0.002 R2 = 0.999

Concentration (^g/mL)

+ Series 1 - Linear (series 1)

Figure 5: Calibration graph for FLU.

Table 4: Precision results for PAR and FLU.

Parameters Sampling time Amount present (mg) PAR Amount present (%) RSD (%) Amount present (mg) FLU Amount present (%) RSD (%)

Repeatability (« = 3) 0hrs 8th hrs 326.61 327.85 100.49 ± 0.46 100.87 ± 0.49 0.46 0.48 100.61 100.08 100.61 ±0.98 100.08 ± 1.20 0.97 1.20

16th hrs 326.90 100.58 ±0.25 0.25 98.76 98.76 ± 0.36 0.36

1st day 328.30 100.93 ±0.52 0.51 101.40 101.40 ±0.75 0.74

2nd day 325.12 100.03 ±0.12 0.12 100.88 100.88 ±0.59 0.58

Intermediate 3rd day 325.61 100.19 ±0.10 0.10 98.62 98.62 ± 0.29 0.30

precision Analyst-1 326.33 100.41 ± 0.33 0.33 101.14 101.14 ±0.46 0.46

(n = 6) Analyst-2 325.50 100.15 ±0.03 0.03 100.88 100.88 ±0.59 0.58

Instrument-1 326.12 100.34 ±0.17 0.17 100.51 100.51 ±0.98 0.97

Instrument-2 325.95 100.29 ± 0.22 0.22 100.12 100.12 ± 1.00 1.0037

Reproducibility Lab-1 325.51 100.15 ±0.12 0.12 99.23 99.23 ± 0.38 0.36

(« = 6) Lab-2 325.17 100.05 ± 0.20 0.20 100.24 100.24 ±0.38 0.37

The low % RSD (<2%) for PAR and FLU indicated that the method is precise.

Table 5: Results observed by changing the wavelength ± 1 nm.

Wavelength (nm)

Amount present (mg)

Amount present (%)

Wavelength (nm)

Amount present (mg)

Amount present (%)

244 (n = 3) 323'95 99.67 ±0.10 0.10 343.5 (« = 3) 97.96 97.96 ± 0.76 0.78

246 3) 322.49 (« = 3) 99.23 ± 0.24 0.24 345.5 (« = 3) 97.96 97.96 ±0.38 0.39

The % RSD value calculated from the robustness study was found to be less than 2 % for PAR and FLU, indicating that the method is robust.

Table 6: Assay results of tablets dosage forms.

PAR FLU

Amount present (mg) Amount present (% Label claim) Amount present (mg) Amount present (% Label claim)

324.11 99.72 101.05 101.05

322.52 99.23 100.39 100.38

323.35 99.49 99.72 99.72

320.93 98.74 99.72 99.72

322.17 99.13 101.05 101.05

AVG 99.26 AVG 100.38

SD 0.37 SD 0.66

% RSD 0.37 % RSD 0.65

The percentage recovery varied from 99.18 to 100.02 for PAR and 98.47 to 100.09 for FLU, indicating good accuracy of the method.

3.4. Precision. Precision study was established by measuring the absorbance of sample solution without changing the assay procedure and the results were presented in Table 4.

3.5. Repeatability. This study was performed with a minimum of three replicate measurements of absorbance of sample solution at 0 hrs, 8 hrs, and 16 hrs in the same day

3.6. Intermediate Precision. Intermediate precision was performed by measuring the absorbance of sample solution in three different days by different analysts and in different instruments.

3.7. Reproducibility. Reproducibility of the method was checked in two laboratories and the results were compared.

The low % RSD (<2%) for PAR and FLU indicated that the method is precise.

3.8. Robustness. Robustness of the method was determined by changing the wavelength ±1 nm from 245 nm to 344.5 nm and the results were offered in Table 5.

The % RSD value calculated from the robustness study was found to be less than 2% for PAR and FLU, indicating that the method is robust.

3.9. Limit of Detection (LOD) and Limit of Quantification (LOQ). LOD and LOQ were calculated based on the standard deviation of the response (50% concentration solution)

and the slope of calibration graph. LOD and LOQ for PAR and FLU were found to be 185.91 ng/mL and 563.38 ng/mL for PAR and 78.89 ng/mL and 239.06 ng/mL for FLU.

3.10. Stability. Stability of the standard and sample solutions were checked for three days at room temperature and the absorbance was measured on each day. Amount of drug present in the sample solution was calculated and the results confirmed that the sample solution is stable for three days without any degradation at room temperature.

3.11. Application of Developed Method to Marketed Dosage Forms. 20 tablets were weighed and flattened into powder. Powder weight equivalent to 12.500 mg of PAR and 3.846 mg of FLU were transferred into a 100 mL volumetric flask. 50 mL of solvent was added and sonicated for 20 minutes. Then the final volume was diluted up to the mark with the solvent (0.1 N HCl) and filtered. 2mL of the above filtrate was transferred into a 25 mL volumetric flask, and the final volume was adjusted up to mark with the same solvent to get sample solution with the concentration of 10 ^g/mL of PAR and 3.07 ^g/mL of FLU. The absorbance of the resulting solution was measured at 245 and 344.5 nm and the amount of PAR and FLU present in each tablet was found to be 325 mg and 100 mg, respectively. The assay results were described in Table 6.

Finally the developed new simple simultaneous equation method was applied successfully to the marketed tablet dosage form and the assay results were indicating that this method can be effectively used for the estimation of both drugs in combined dosage form.

4. Conclusion

The developed simultaneous equation method is simple, precise, specific, and accurate. Statistical analysis proved that the method was repeatable and selective for the simultaneous estimation of PAR and FLU in pure and pharmaceutical dosage forms without any interference from the excipients. This new simple method can be used routinely for the estimation of these drugs.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

[1] S. R. Pattan, S. G. Jamdar, R. K. Godge et al., "RP- HPLC method for simultaneous estimation of paracetamol and etoricoxib from bulk and tablets," Journal of Chemical and Pharmaceutical Research, vol. 1, no. 1, pp. 329-335, 2009.

[2] D. Amal and T. P. Aneesh, "Method development and validation for the estimation of flupirtine maleate in bulk and pharmaceutical dosage forms using UV-VIS spectrophotometry," International Research Journal of Pharmacy, vol. 2, no. 12, pp. 179-182, 2011.

[3] S. Behera, S. Ghanty, F. Ahmad, S. Santra, and S. Banerjee, "UV-visible spectrophotometry method development and validation of assay of paracetamol tablet formulation," Journal of Analytical and Bioanalytical Techniques, vol. 3, no. 6, article 151, 2012.

[4] K. Kapil, S. Naik, J. Garima, and N. Mishra, "Spectrophoto-metric method for simultaneous estimation of paracetamol and domperidone in tablet formulation," Asian Journal of Research in Chemistry, vol. 2, no. 2, pp. 112-114, 2009.

[5] A. R. Rote, P. A. Kumbhoje, and R. S. Bhambar, "UV-visible spectrophotometric simultaneous estimation of paracetamol and nabumetone by AUC method in combined tablet dosage form," Pharmaceutical Methods, vol. 3, no. 1, pp. 40-43, 2012.

[6] S. G. Khanage, P. B. Mohite, and S. Jadhav, "Development and validation of UV-visible spectrophotometric method for simultaneous determination of eperisone and paracetamol in solid dosage form," Advanced Pharmaceutical Bulletin, vol. 3, no.

2, pp. 447-451, 2013.

[7] A. M. Kumar, A. Swathi, D. Supriya, V. V. L. N. Prasad, and P. V. Diwan, "Development and validation of the UV spectrophotometric method for simultaneous estimation of ibuprofen, paracetamol and caffeine in pharmaceutical dosage form," American Journal ofPharm Tech Research, vol. 2, no. 6, pp. 540-547, 2012.

[8] U. Shah, M. Kavad, and M. Raval, "Development and validation of UV spectrophotometric method for estimation of paracetamol and flupirtine maleate in bulk and pharmaceutical dosage form," International Journal of PharmTech Research, vol. 5, no.

3, pp. 1007-1113, 2013.

[9] S. S. Chitlange, R. Soni, S. B. Wankhede, and A. A. Kulkarni, "Spectrophotometric methods for simultaneous estimation of dexibuprofen and paracetamol," Asian Journal of Research in Chemistry, vol. 2, no. 1, pp. 30-33, 2009.

[10] S. Gangishetty and S. Verma, "RP-HPLC method development and validation for simultaneous estimation of clarithromycin

and paracetamol," ISRN Analytical Chemistry, vol. 2013, Article ID 948547, 5 pages, 2013.

[11] M. Attimarad, "Simultaneous determination of paracetamol and lornoxicam by RP-HPLC in bulk and tablet formulation," Pharmaceutical Methods, vol. 2, no. 1, pp. 61-66, 2011.

[12] A. P. Dewani, S. M. Dabhade, R. L. Bakal, C. K. Gadewar, A. V. Chandewar, and S. Patra, "Development and validation of a novel RP-HPLC method for simultaneous determination of paracetamol, phenylephrine hydrochloride, caffeine, cetirizine and nimesulide in tablet formulation," Arabian Journal of Chemistry, 2013.

[13] R. Chandra and K. D. Sharma, "Quantitative determination of paracetamol and caffeine from formulated tablets by reversed phase-HPLC separation technique," International Journal of Chromatographic Science, vol. 3, no. 2, pp. 31-34, 2013.

[14] K. V. Lalitha, G. M. M. Reddy, J. R. Reddy, K. V Kumar, and A. Aliekya, "RP-HPLC method development and validation for the simultaneous estimation of paracetamol and flupiritine maleate in pharmaceutical dosage forms," Journal of Scientific and Innovative Research, vol. 2, no. 3, pp. 634-641, 2013.

[15] S. Kathirvel, R. Sujatha, M. R. Pandit, and A. Suneetha, "Stress degradation studies on flupirtine maleate using stability-indicating RP-HPLC method," Chromatography Research International, vol. 2013, Article ID 941429, 6 pages, 2013.

[16] T. S. Mulla, J. R. Rao, S. S. Yadav, V. V. Bherekar, and M. P. Rajput, "Development and validation of HPLC method for simultaneous quantitation of paracetamol and dexketoprofen trometamol in bulk drug and formulation," International Journal of Comprehensive Pharmacy, vol. 2, no. 7, pp. 1-4, 2011.

[17] T. Raja and A. Lakshmana Rao, "Validated HPTLC method for simultaneous quantitation of paracetamol and lornoxicam in bulk drug and pharmaceutical formulation," International Journal of Pharmaceutical and Biomedical Research, vol. 3, no. 3, pp. 162-166, 2012.

[18] K. Kandasamy, V. S. Gowdra, H. Nammalvar, and A. K. K. S. Govindarajan, "Bioanalytical method development, validation and quantification of flupirtine maleate in rat plasma by liquid chromatography-tandem mass spectrometry," Arzneimittel Forschung—Drug Research, vol. 61, no. 12, pp. 693-699, 2011.

[19] G. H. Jefferey, J. Basset, J. Mendham, and R. C. Denney, Vogel's Textbook of Quantitative Chemical analysis, Longman, London, UK, 5th edition, 1989.

[20] A. H. Beckett and J. B. Stenlake, Practical Pharmaceutical Chemistry, vol. 2, CBS, New Delhi, India, 4th edition, 1997.

[21] P. R. Shetty and D. D. Patil, "Applications of simultaneous equation method and derivative method for the determination of rabeprazole sodium and levosulpiride in pharmaceutical dosage form and dissolution samples," Journal of the Association of Arab Universities for Basic and Applied Sciences, vol. 15, pp. 53-60, 2014.

[22] P. Giriraj and T. Sivakkumar, "Simultaneous estimation of dutasteride and tamsulosin hydrochloride in tablet dosage form by vierordt's method," Arabian Journal of Chemistry, 2013.

[23] F. Khan, R. T. Lohiya, and M. J. Umekar, "Development of UV spectrophotometric method for the simultaneous estimation of meloxicam and paracetamol in tablet by simultaneous equation, absorbance ratio and absorbance correction method," International Journal ofChemTech Research, vol. 2, no. 3, pp. 1586-1591, 2010.

[24] "ICH: Harmonized Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology Q2 (R1)," Geneva, Switzerland, 2005.

Copyright of International Journal of Spectroscopy is the property of Hindawi Publishing Corporation and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.